|
Gene: CHST6 |
Gene summary for CHST6 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CHST6 | Gene ID | 4166 |
Gene name | carbohydrate sulfotransferase 6 | |
Gene Alias | C-GlcNAc6ST | |
Cytomap | 16q23.1 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | Q9GZX3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4166 | CHST6 | HCC1 | Human | Liver | HCC | 4.08e-22 | 1.88e+00 | 0.5336 |
4166 | CHST6 | HCC2 | Human | Liver | HCC | 1.80e-31 | 2.05e+00 | 0.5341 |
4166 | CHST6 | HCC5 | Human | Liver | HCC | 1.53e-37 | 2.07e+00 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000679021 | Liver | HCC | sulfur compound metabolic process | 212/7958 | 339/18723 | 5.60e-14 | 3.39e-12 | 212 |
GO:00442722 | Liver | HCC | sulfur compound biosynthetic process | 95/7958 | 148/18723 | 7.89e-08 | 1.58e-06 | 95 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CHST6 | SNV | Missense_Mutation | rs766513942 | c.659N>T | p.Arg220Leu | p.R220L | Q9GZX3 | protein_coding | tolerated(0.39) | benign(0.175) | TCGA-97-A4LX-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CHST6 | SNV | Missense_Mutation | novel | c.598N>A | p.Leu200Met | p.L200M | Q9GZX3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-NJ-A55R-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CHST6 | SNV | Missense_Mutation | c.530N>A | p.Arg177His | p.R177H | Q9GZX3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-21-1080-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CHST6 | SNV | Missense_Mutation | c.1145N>A | p.Gly382Asp | p.G382D | Q9GZX3 | protein_coding | tolerated(0.34) | benign(0.01) | TCGA-22-4595-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | alimta | PD | |
CHST6 | SNV | Missense_Mutation | rs750187166 | c.766G>A | p.Ala256Thr | p.A256T | Q9GZX3 | protein_coding | deleterious(0.02) | probably_damaging(0.984) | TCGA-33-4538-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
CHST6 | SNV | Missense_Mutation | novel | c.174A>T | p.Gln58His | p.Q58H | Q9GZX3 | protein_coding | deleterious(0.02) | possibly_damaging(0.861) | TCGA-34-2608-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CHST6 | SNV | Missense_Mutation | c.166N>T | p.Val56Leu | p.V56L | Q9GZX3 | protein_coding | tolerated(0.36) | benign(0.075) | TCGA-37-5819-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
CHST6 | SNV | Missense_Mutation | novel | c.1144N>T | p.Gly382Cys | p.G382C | Q9GZX3 | protein_coding | deleterious(0.03) | benign(0.263) | TCGA-43-2576-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
CHST6 | SNV | Missense_Mutation | novel | c.349C>G | p.Leu117Val | p.L117V | Q9GZX3 | protein_coding | tolerated(0.76) | benign(0.012) | TCGA-56-A49D-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
CHST6 | SNV | Missense_Mutation | novel | c.1093N>T | p.Asp365Tyr | p.D365Y | Q9GZX3 | protein_coding | deleterious(0.01) | benign(0.078) | TCGA-63-A5MB-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |